Literature DB >> 15983443

The characteristics of disseminated tumor cells in pancreatic cancer: a black box needs to be explored.

Dongming Su1, Koji Yamaguchi, Masao Tanaka.   

Abstract

Despite recent advances in early diagnosis and surgical treatment, the clinical outcome of patients with pancreatic cancer has not been improved markedly. One of the reasons for the dismal outcome is early dissemination of tumor cells. Sensitive immunohistocytochemical and nucleic acid-based assays have detected disseminated tumor cells in the lymph nodes, bone marrow, peritoneal cavity or peripheral blood. Formation of the metastatic disease depends on the nature of the disseminated tumor cells. Standardization of protocols is mandatory to detect occult tumor cells in clinical practice. We present an overview of recent studies on the incidence, prognostic values and some characteristics of occult tumor cells disseminated in the secondary sites of patients with pancreatic cancer. Copyright 2005 S. Karger AG, Basel and IAP.

Entities:  

Mesh:

Year:  2005        PMID: 15983443     DOI: 10.1159/000086532

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  9 in total

Review 1.  Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?

Authors:  Sunny Y Wong; Richard O Hynes
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

2.  Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.

Authors:  Feihu Bai; Jie Liang; Jun Wang; Yongquan Shi; Kedong Zhang; Shuhui Liang; Liu Hong; Huihong Zhai; Yuanyuan Lu; Yu Han; Fang Yin; Kaichun Wu; Daiming Fan
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

3.  MicroRNA-452 suppresses pancreatic cancer migration and invasion by directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1.

Authors:  Hongyan Li; Yan Wu; Peixiu Li
Journal:  Oncol Lett       Date:  2017-07-10       Impact factor: 2.967

Review 4.  Postsurgery activation of dormant liver micrometastasis: a case report and review of literature.

Authors:  Bert Deylgat; Frank Van Rooy; Franky Vansteenkiste; Dirk Devriendt; Christophe George
Journal:  J Gastrointest Cancer       Date:  2011-03

5.  Pancreatic cancer--low survival rates.

Authors:  Hans G Beger; Bettina Rau; Frank Gansauge; Gerd Leder; Michael Schwarz; Bertram Poch
Journal:  Dtsch Arztebl Int       Date:  2008-04-04       Impact factor: 5.594

6.  Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.

Authors:  Christian Dittrich; Robert Königsberg; Martina Mittlböck; Klaus Geissler; Azra Sahmanovic-Hrgovcic; Johannes Pleiner-Duxneuner; Martin Czejka; Philipp Buchner
Journal:  Invest New Drugs       Date:  2018-07-12       Impact factor: 3.850

7.  MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.

Authors:  Xiang Xia; Kundong Zhang; Gang Cen; Tao Jiang; Jun Cao; Kejian Huang; Chen Huang; Qian Zhao; Zhengjun Qiu
Journal:  Oncotarget       Date:  2015-08-28

8.  Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma.

Authors:  Yunchao Wang; Jian Li; Shixiang Guo; Yongsheng Ouyang; Liangyu Yin; Songsong Liu; Zhiping Zhao; Jiali Yang; Wenjie Huang; Huan Qin; Xin Zhao; Bing Ni; Huaizhi Wang
Journal:  Oncotarget       Date:  2017-07-26

9.  MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway.

Authors:  Xin Sui; Zhenghui Sui
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.